Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line
İZ Durusu, HH Hüsnügil, H Ataş, A Biber, S Gerekçi… - Leukemia Research, 2017 - Elsevier
Multiple Myeloma (MM) is a malignant neoplasm of bone marrow plasma B cells with high
morbidity. Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-
inflammatory drug that was previously shown to have growth suppression effect on various
cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as
well as melanoma, neuroblastoma, and leukemia. The objective of this study was to
evaluate the anticancer effect and mechanism of CLF on U266 MM cell line. CLF (10 μM, 24 …
morbidity. Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-
inflammatory drug that was previously shown to have growth suppression effect on various
cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as
well as melanoma, neuroblastoma, and leukemia. The objective of this study was to
evaluate the anticancer effect and mechanism of CLF on U266 MM cell line. CLF (10 μM, 24 …